Gorman Kevin Charles's Form 4 filing
Neurocrine Biosciences Inc (NBIX) · filed Aug 11, 2025
- Accession no.
- 0000914475-25-000166
- Filed
- Aug 11, 2025
- Trade date
- Aug 7, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $13.4M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Gorman Kevin CharlesCIK 0001201096 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 7, 2025 | Common Stock | MOption exerciseAcquired | +106,322 | $35.99 | +$3,826,528.78 | 620,918 | Direct | |
| Aug 7, 2025 | Common Stock | SSaleDisposed | −106,322 | $126.41 | −$13,440,164.02 | 514,596 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 7, 2025 | Common Stock | MOption exerciseDisposed | −106,322 | $0.00 | $0 | 0 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.